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ABSTRACT
It has been hypothesized that the paclitaxel vehicle
Cremophor EL (CrEL) is responsible for nonlinear drug
disposition by micellar entrapment. To gain further insight
into the role of CrEL in taxane pharmacology, we studied
the pharmacokinetics of paclitaxel in the presence and ab-
sence of CrEL after i.p. and i.v. dosing. Patients received an
i.p. tracer dose of [G-3H]paclitaxel in ethanol without CrEL
(100 Ci diluted further in isotonic saline) on day 1, i.p.
paclitaxel formulated in CrEL (Taxol; 125 mg/m2) on day 4,
an i.v. tracer of [G-3H]paclitaxel on day 22, and i.v. Taxol
(175 mg/m2) on day 24. Four patients (age range, 54–74
years) were studied, and serial plasma samples up to 72 h
were obtained and analyzed for total radioactivity, pacli-
taxel, and CrEL. In the presence of CrEL, i.v. paclitaxel
clearance was 10.2  3.76 liters/h/m2 (mean  SD), consist-
ent with previous findings. The terminal disposition half-life
was substantially prolonged after i.p. dosing (17.0  11.3
versus 28.7  8.72 h), as was the mean residence time
(7.28  2.76 versus 40.7  13.8 h). The bioavailability of
paclitaxel was 31.4  5.18%, indicating insignificant sys-
temic concentrations after i.p. treatment. CrEL levels were
undetectable after i.p. dosing (<0.05 l/ml), whereas after
i.v. dosing, the mean clearance was 159  58.4 ml/h/m2, in
line with earlier observations. In the absence of CrEL, the
bioavailability and systemic concentrations of i.p. paclitaxel
were significantly increased. This finding is consistent with
the postulated concept that CrEL is largely responsible for
the pharmacokinetic advantage for peritoneal cavity expo-
sure to total paclitaxel compared with systemic delivery.
INTRODUCTION
The role of i.p. chemotherapy for tumors principally con-
fined to the peritoneal cavity has been studied extensively (1).
Although it has proven to be a safe procedure with encouraging
results, it has not yet become a standard therapeutic procedure
(1, 2). The major goal of this therapeutic strategy is to expose
tumors within the peritoneal cavity to higher concentrations of
antineoplastic agents for longer periods of time than can be
achieved with systemic drug administration. i.p. treatment with
paclitaxel is particularly attractive in patients with ovarian can-
cer (3–6), because i.v. paclitaxel has proven single-agent activ-
ity in ovarian cancer (7, 8), and also potentially in other tumor
types confined to the abdominal cavity, such as peritoneal
mesothelioma (9, 10). The antitumor effect is dependent on
duration of exposure, on the drug concentration in contact with
the tumor, and in the case of paclitaxel, on the unique pharma-
cokinetic profile of paclitaxel and its solvent vehicle CrEL,3 a
nonionic castor oil derivative.
It has been demonstrated that at high local concentrations,
which can be reached by i.v. and especially by i.p. administra-
tion, paclitaxel is entrapped in CrEL micelles (11). Our hypoth-
esis is that this phenomenon accounts for the prolonged (peri-
toneal) activity at high concentrations as reported for
intravesical treatment (12) and that, hence, paclitaxel distribu-
tion will depend on CrEL pharmacokinetics. To gain further
insight into the role of CrEL in the pharmacokinetic behavior of
paclitaxel, we studied paclitaxel disposition in cancer patients,
with the drug formulated in the presence and absence of CrEL,
after i.p. and i.v. dosing.
MATERIALS AND METHODS
Materials and Chemicals. [G-3H]Paclitaxel with a spe-
cific activity of 2.4 Ci/mmol was obtained from Moravek Bio-
chemicals, Inc. (Brea, CA). The majority of the tritium is in the
m and p positions of the aromatic rings, with minor amounts in
the 10, 3, and 2 positions of the taxane ring system. The clinical
paclitaxel formulation in CrEL and dehydrated USP-grade eth-
anol (1:1, v/v; Taxol) and paclitaxel powder were purchased
from Bristol-Myers Squibb (Woerden, the Netherlands). The
CrEL reference material was obtained from Sigma Chemical
Co. (St. Louis, MO) and Coomassie brilliant blue G-250 from
Bio-Rad Laboratories (Munich, Germany) as a concentrated
solution in 85% (w/v) phosphoric acid-95% (v/v) ethanol (2:1,
v/v). All other chemicals and reagents used were of reagent
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grade or better and originated from Rathburn (Walkerburn,
United Kingdom). HPLC-grade water was obtained from a
Millipore (Milford, MA) Milli-Q-UF system. Ultima Gold scin-
tillation cocktail was purchased from Packard (Meriden, CT).
The internal standard for quantitative paclitaxel analysis, do-
cetaxel, was obtained from Aventis (Vitry-sur-Seine Cedex,
France).
Patients. Eligible patients had a histologically or cyto-
logically verified cancer with tumor morbidity attributable to
localization in the abdominal cavity, for which treatment with
paclitaxel was a reasonable option or for which no effective
therapy was available. Other inclusion criteria included (a) age
at least 18 years, (b) WHO performance status 2, (c) no
previous chemotherapy and/or radiotherapy in the past 4 weeks,
(d) adequate hematopoietic function (absolute neutrophil count
1.5  109/liter and platelet count 100  109/liter), and (e)
adequate hepatic function (total serum bilirubin level 1.25
times the upper limit of normal). Specific exclusion criteria
included (a) signs of bowel obstruction and (b) peripheral neu-
ropathy graded 1 (National Cancer Institute common toxicity
criteria). The study protocol was approved by the medical eth-
ical committee of the Rotterdam Cancer Institute, and all pa-
tients gave written informed consent before study entry.
Treatment Plan. All patients received one administra-
tion of CrEL-free i.p [G-3H]paclitaxel (100 Ci; 0.1 mg) on
day 1 and one administration of i.p. (unlabeled) paclitaxel in
CrEL-ethanol (Taxol) at a dose of 125 mg/m2 (based on a
previous Phase I study; Ref. 3) on day 4, followed by one
administration of CrEL-free i.v. [G-3H]paclitaxel (100 Ci) on
day 22 and one i.v. administration of Taxol at a dose of 175
mg/m2 on day 25. The i.p. administrations were performed by
repeated paracentesis placed under sterile conditions after sono-
graphic localization, which is a safe and practical method for i.p.
chemotherapy (13). All ascites was drained before each i.p.
infusion. Paclitaxel for i.p. dosing, either unlabeled or labeled,
was administered in 2 liters of isotonic sodium chloride (0.9%,
w/v), preheated to 37°C. The i.p infusion was administered in 45
min and the i.v. administrations in 3 h, also in a volume of 2
liters of isotonic sodium chloride. Polyvinyl chloride-containing
infusion systems were avoided because CrEL is known to leach
plasticizers from these products. Instead, cellulose acetate filters
(0.22 m pore size) were used for infusions. Before i.v. infu-
sion, patients were premedicated with ranitidine (50 mg), clem-
astine (2 mg), and dexamethasone (10 mg), all 30 min before all
drug administrations.
The total dose of radioactivity delivered to the patients and
the small dose of non-CrEL-bound paclitaxel were nonhazard-
ous, and no special additional precautions were necessary (14,
15). During the first 2 h after the i.p. administration of paclitaxel
was started, patients were encouraged to change positions every
15 min to maintain adequate distribution throughout the perito-
neal cavity.
Clinical Assessment. Before therapy, a complete medi-
cal history was taken and a physical examination was per-
formed. A complete blood cell count, including WBCs, differ-
ential, and serum biochemistry, was performed before treatment,
as was disease evaluation. During treatment, patients were seen
at least weekly by a physician, and complete blood cell counts
and serum chemistries were monitored weekly.
Pharmacological Analysis. Venous blood samples of 5
ml were obtained in the two i.p. cycles at the following time
points: before infusion; at 15, 30, and 40 min during instillation;
and at 5, 15, and 30 min and 1, 2, 4, 8, 10, 21, 24, 48, and 72 h
post instillation. For the two i.v. cycles, blood samples were
collected at 0.5, 1, 1.5, 2, 2.5, and 2.55 h during infusion and at
5, 15, 30, and 45 min and 1, 2, 4, 8, 10, and 21 h post infusion.
Samples were collected in tubes containing potassium EDTA as
anticoagulant, and centrifuged to obtain the plasma supernatant
(3000  g for 10 min). Duplicate ascitic samples were obtained
in one patient after the second i.p. administration immediately
after the end of infusion and 4, 6, and 18 days after the end of
infusion and in another patient after the second i.v. administra-
tion at 1.5 and 3 h after start of infusion. These samples were
obtained with a Medicut 16-gauge cannula (45  1.7 mm
internal diameter; Sherwood Medical, Tullamore, Ireland), col-
lected in 4.5-ml polypropylene tubes (after the first 10 ml of
fluid was discard), and processed as described above for plasma.
Fig. 1 Representative reversed-phase chromatographic tracings
with UV detection (solid lines) and off-line liquid scintillation count-
ing (dashed lines; 1-min fractions) of plasma extracts taken from
samples collected from a patient at the end of a 3-h i.v. infusion of
CrEL-free [G-3H]paclitaxel (100 Ci) on day 22, and a 3-h i.v.
infusion of Taxol (175 mg/m2) on day 25. Chromatographic peaks in
the plot with UV detection correspond to unchanged paclitaxel
[retention time (tR)  5.81 min] and the internal standard, docetaxel
(tR  6.40 min; A). The presently identified paclitaxel metabolites
6,3-p-dihydroxypaclitaxel (tR  2.63 min), 3-p-hydroxypaclitaxel
(tR  3.09 min), and 6-hydroxypaclitaxel (tR  4.56 min) could not
be detected in the plasma samples (B). Reference standards of the
metabolites for determination of chromatographic retention times
were obtained as described previously (16).
Table 1 Patient characteristics
Characteristic Median (range)
Number of patients 4
Age (yrs) 64 (54–74)
Sex (F/M) 4/0
Weight (kg) 66 (55–72)
Height (cm) 168 (163–173)
Body-surface area (m2) 1.70 (1.50–1.80)
Tumor type Mesothelioma (n  2);
ovarian carcinoma (n  2)
Toxicity Only mild gastrointestinal
and hematological
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Plasma and ascitic fluid samples were analyzed for the
presence of paclitaxel and CrEL by HPLC with UV detection
(16) and a colorimetric dye-binding microassay (17), respec-
tively. The handling and measurement of [G-3H]paclitaxel was
performed according to a protocol approved by the local Radi-
ation Approval Committee of the Rotterdam Cancer Institute as
described in detail elsewhere (15). Briefly, radioactivity was
determined by liquid scintillation counting after the addition of
Ultima Gold scintillation cocktail (Turku, Finland). All samples
were counted until a preset time of 20 min was reached, with
quench correction performed by external standardization.
Concentration-time profiles for paclitaxel and total radio-
activity were analyzed by noncompartmental modeling using
Siphar V4 (InnaPhase, Philadelphia, PA). The AUC was calcu-
lated by the linear trapezoidal rule with extrapolation to infinity,
and the apparent plasma clearance was calculated as the ratio of
dose delivered (in mg/m2) and AUC. On the basis of the known
pharmacological properties of paclitaxel after i.v. administration
(15), we anticipated that circulating paclitaxel metabolite con-
centrations would be very low. Indeed, analysis of extracted
patient samples indicated that none of the paclitaxel metabolites
identified at present (6,3-p-dihydroxypaclitaxel, 3-p-
hydroxypaclitaxel, and 6-hydroxypaclitaxel) was detected at
any time point in any patient after i.v. or i.p. drug administration
of paclitaxel when formulated in CrEL (Fig. 1). This suggests
that concentrations were always lower than the lower limit of
quantitation of our HPLC assay (i.e., 10 ng/ml). Thus, because
the paclitaxel metabolites are not contributing significantly to
total circulating drug, the total radioactivity was equated with
the (unchanged) parent drug concentration. In the pharmacoki-
netic data analysis, we also assumed that partitioning of pacli-
taxel out of CrEL micelles occurs rapidly (i.e., much faster than
the partitioning into tissues/cells), which establishes this process
as an unimportant kinetic process, and assumed that the two
entities were interchangeable. This assumption is based on pre-
vious observations that in vitro equilibrium between paclitaxel
in CrEL micelles and free paclitaxel (outside micelles) was
reached within 1 min (18). This can be considered instantaneous
on the time scale of paclitaxel pharmacokinetics both after i.v.
and especially after i.p. drug administration.
The bioavailability (F) for i.p. paclitaxel was calculated as:
F  (AUCi.p./AUCi.v.)  (dosei.v./dosei.p.)  100%. All phar-
macokinetic parameters were determined from the data obtained
with the full nonradioactive dose and represent dose-normalized
mean values (to 125 mg/m2 for i.p. and to 175 mg/m2 for i.v.)
with SDs. Statistical evaluation was performed with the NCSS
package V5.X (J. Hintze, East Kaysville, UT), using the non-
parametric Wilcoxon test for matched pairs. The level of sig-
nificance was set at P  0.05.
RESULTS
Patient Characteristics and Toxicity. Of six eligible
patients, two withdrew consent before the second i.p. infusion of
paclitaxel because of rapid progressive disease (one patient) or
nonrelated and unexpected occurrence of psychiatric illness
(one patient). Four patients received the four planned adminis-
trations of paclitaxel, and all were pharmacologically evaluable.
The patient characteristics are summarized in Table 1. Overall,
the treatment was very well tolerated, with no infusion-related
complications and no grade 3–4 hematological and nonhema-
tological toxicity. Disease stabilization was initially obtained in
all four patients.
Plasma Pharmacokinetics. The pharmacokinetic data
for i.p.- and i.v.-delivered paclitaxel in the presence and absence
of CrEL are shown in Table 2. In the presence of CrEL, the
terminal disposition half-life of paclitaxel was substantially pro-
longed after i.p. dosing compared with i.v. dosing (28.7 	 8.72
versus 17.0 	 11.3 h; P  0.006), as was the mean residence
time (40.7 	 13.8 versus 7.28 	 2.76 h; P  0.005; Fig. 2),
which may be advantageous for local antitumor effects. The
bioavailability of i.p.-delivered paclitaxel formulated in CrEL
was only 31.4 	 5.18%, indicating low concentrations within
the systemic compartment. However, in the absence of CrEL,
the bioavailability (98.8 	 16.6 versus 31.4 	 5.18%; P 
0.005) and systemic exposure (7.55 	 3.38 versus 5.04 	 1.92
M  h; P 0.064) of i.p.-delivered paclitaxel were significantly
increased, which may eventually lead to increases in systemic
(hematological) toxicity.
The systemic CrEL levels were undetectable after i.p.
dosing of paclitaxel (0.05 l/ml), whereas after i.v. dosing, the
mean clearance of CrEL was 159 	 58.4 ml/h/m2, in line with
previous observations (19, 20).
Fig. 2 Representative plasma concentration-time profiles of total
paclitaxel after i.p. (E) and i.v. (F) delivery of paclitaxel formulated in
a mixture of CrEL and USP-grade ethanol (1:1, v/v).
Table 2 Plasma pharmacokinetics of i.p. and i.v. paclitaxel
Parameter 
CrEL (Taxol) CrEL P
i.p. dosing
cmax
b (M) 0.14 	 0.08 0.26 	 0.07 0.12
AUC (Mh) 5.04 	 1.92 7.55 	 3.38 0.064
MRT (h) 40.7 	 13.8 7.28 	 2.76 0.003
F (%) 31.4 	 5.18 98.8 	 16.6 0.005
i.v. dosing
cmax (M) 5.44 	 1.76 3.63 	 1.56 0.054
AUC (Mh) 22.9 	 10.0 11.4 	 6.50 0.011
CL (liters/h/m2) 10.2 	 3.76 22.8 	 11.7 0.027
a Wilcoxon test for matched pairs.
b cmax, peak plasma concentration; MRT, mean residence time; F,
bioavailability for i.p. administration; CL, clearance.
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Ascitic Fluid Penetration. Given the relatively high to-
tal protein content in the ascites of the patients (range, 38–45
mg/ml), no correction for protein binding was performed. After
i.p. administration in the presence of CrEL, the paclitaxel con-
centration peaked immediately after the end of instillation at
levels 1600-fold higher than concomitant plasma concentra-
tions. Paclitaxel elimination from ascites was extremely slow,
with detectable levels (10.2 ng/ml) even at 18 days after
dosing and an apparent disappearance half-life of 140 h. In
contrast, measurement of paclitaxel in ascites after i.v. admin-
istration with CrEL indicated that 1.3% of systemic concen-
trations were present in ascites, indicating lack of a sink effect.
DISCUSSION
The results of the present study show that the use of
CrEL as a formulation vehicle results in a drastic alteration in
the pharmacokinetics of paclitaxel after i.p. or i.v. adminis-
tration. Indeed, the presence of CrEL in the pharmaceutical
formulation (Taxol) leads to a substantial decrease in the
bioavailability after i.p. drug administration (31.4 versus
98.8%). The overall result is a 50% decrease in the paclitaxel
plasma AUC after i.p. administration and a 100% increase
after i.v. administration.
The human pharmacokinetics of paclitaxel after i.v. admin-
istration have been studied extensively using sensitive and se-
lective HPLC methods (18, 21, 22). Because the normal phar-
maceutical formulation already contains significant amounts of
CrEL, we used an i.v. formulation that does not contain this
vehicle substance to allow determination of comparative phar-
macokinetic profiles. Because paclitaxel without its solvent
CrEL is not registered for human use, we were required to use
a nonhazardous radiolabeled tracer dose. Thus, we compared
therapeutic doses of paclitaxel with CrEL to very small doses of
paclitaxel without CrEL and dose-normalized the pharmacoki-
netic data. Theoretically, this might introduce a methodological
flaw, as has been described previously for some agents (23).
However, the altered disposition of drugs when tracer doses are
used compared with pharmacological doses has been shown to
be caused by the variable degree in saturation of enzymes
involved in (hepatic) biotransformation. It has been shown pre-
viously, for example, that tracer doses of erythromycin produce
aberrant metabolic profiles and therefore altered drug clearance,
and administration of therapeutic doses along with the radiola-
beled tracer in those cases has been advocated (24). However, it
is highly unlikely that this also accounts for the observed dif-
ferences in paclitaxel pharmacokinetics, because: (a) The ap-
parent Michaelis-Menten constant (i.e., Km) and the maximum
reaction velocity (i.e., Vmax) values for the principal metabolic
route, i.e., paclitaxel 6-hydroxylation, were 5.4 	 1.0 M and
30	 1.5 nmol/min/nmol of cytochrome P-450, respectively, for
cDNA-expressed cytochrome P-450 isoform 2C8; the values
were 4.0 	 1.0 M and 0.87 	 0.06 nmol/min/mg of protein,
respectively, for human hepatic microsomes (25). These values
are 50–100-fold higher than peak concentrations of unbound
paclitaxel after therapeutic doses (135–225 mg/m2) in patients
receiving 1-, 3-, or 24-h i.v. infusions (22). (b) The binding of
paclitaxel by plasma proteins (26, 27) and the erythrocyte par-
titioning of paclitaxel in human samples (11) have previously
been shown to be independent of the paclitaxel concentration
within the therapeutic range associated with 3-h i.v. infusions.
(c) No signs of nonlinearity in paclitaxel distribution [unbound
(28), whole blood (21), and tissue concentrations (29, 30)] and
elimination [urinary and fecal concentrations (21)] have been
noted previously.
After i.p. administration, paclitaxel concentrations in
plasma were initially less than those after i.v. administration,
and several hours were required for equilibrium to be attained
between the peritoneal cavity and the systemic circulation. The
limited surface area for paclitaxel diffusion relative to the vol-
umes of fluid and the fact that the peritoneal fluids are not well
stirred likely contributed to the slow equilibrium kinetics. Nev-
ertheless, concentrations in plasma equivalent to those after i.v.
administration were achieved after 20 h in all patients, and
paclitaxel appeared to be more slowly eliminated from the
peritoneal cavity than from plasma. This is in keeping with
earlier findings, which we now confirm, indicating slow perito-
neal clearance of paclitaxel and high peritonea-plasma concen-
tration ratios of 1000 after i.p. drug administration (3). These
authors also documented the persistence of significant perito-
neal paclitaxel levels even at 1 week after initial i.p. drug
administration, already suggesting very slow peritoneal clear-
ance and continuous exposure of the peritoneal cavity to active
concentrations of paclitaxel (4). Thus, although the described
data on paclitaxel accumulation are limited to only four patients,
our results are fully in agreement with previous findings and
suggest that i.p. administration of paclitaxel can produce signif-
icant drug distribution in the peritoneal cavity. In this context, it
is of particular interest that the cytotoxicity of paclitaxel is a
function of the time to drug exposure above a certain threshold
concentration (20, 31). The paclitaxel penetration and subse-
quent accumulation in the peritoneal cavity thus might offer a
potential therapeutic advantage in that tumor cells are exposed
to high local drug levels for prolonged time periods. In contrast,
there appears to be rapid clearance after i.p. paclitaxel admin-
istration without CrEL, with bioavailability approaching unity.
This suggests a reduced ability of paclitaxel to interact with
tubulin or other essential targets as well as an increased risk of
severe (hematological) toxicity in cancer patients treated with
paclitaxel in the absence of CrEL.
We expect that the results presented here for paclitaxel are
representative of other poorly water-soluble drugs formulated in
this vehicle. This is supported by recent observations that sev-
eral commonly used anticancer agents, including anthracyclines
and epipodophyllotoxins, can be readily incorporated into CrEL
micelles (32), thereby strongly affecting the plasma pharmaco-
kinetics (33). This implies that reformulation of hydrophobic
anticancer agents with a vehicle containing CrEL for i.p. treat-
ment might achieve improvement of their therapeutic index.
In conclusion, we have shown that CrEL is mainly respon-
sible for the pharmacokinetic advantage for peritoneal cavity
exposure to total paclitaxel compared with systemic delivery
and compared with a CrEL-free paclitaxel formulation. These
findings provide a rationale for attempts to improve local drug
distribution after i.p. administration of other hydrophobic anti-
cancer agents by concomitant administration of CrEL.
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